You may be interested in these additional resources
Innovation in Rare Oncology Trial Design
Rare afflictions account for up to 30 percent of cancer deaths, and despite medical science’s best efforts, there are still few approved treatments. But drug development innovation through techniques like adaptive trial design is finally improving the outlook for patients. Read our blog.
Target Product Profiles: Turning Discoveries Into Companies
Clinical research’s purpose is to help patients. Too often the human element can get lost in drug development. When designing studies, researchers need to consider the challenges patients and their families face and incorporate the trial innovations oncology patients want. Read our blog.
Complete Response: Lymphoma Trial a Success for 5 Patients
A trans-Atlantic trial of an antibody to treat non-Hodgkin’s lymphoma exceeded expectations nearly three years before its planned completion. Five of 92 patients showed complete response to the CD19 antibody and were cancer-free a year later. Read our case study for the details.